Nona Biosciences Enters Collaboration Agreement with Dragonfly Therapeutics

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to providing a total solution from “Idea to IND”, has entered into a collaboration agreement with Dragonfly Therapeutics based on Nona’s proprietary fully human heavy chain only antibody (HCAb) transgenic mice platform to discover and develop fully human heavy chain only antibodies for bispecific/multi-specific therapeutic antibody generation.
 
Through the collaboration, Nona Biosciences will provide Dragonfly Therapeutics with access to the HCAb technologies as well as antibody generation services for the targets designated by Dragonfly Therapeutics. Financial terms were not disclosed.
 
The collaboration follows Nona’s recently announced license and collaboration agreement with Moderna for nucleic acid-based immunotherapies for select oncology targets. 
 
Dr. Jingsong Wang, founder, chairman, and CEO of Harbour BioMed said: “The Dragonfly Therapeutics’ collaboration recognizes the potential of both our proprietary platform and antibody discovery capabilities. We believe that our HCAb technology together with our accumulated extensive experience in innovative biologics drug discovery will help our partners generate differentiated therapeutic molecules benefiting the patient worldwide.”